Oxford Biomedica (LON:OXB) Posts Quarterly Earnings Results

Oxford Biomedica (LON:OXB) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (41.75) (($0.54)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%.

Oxford Biomedica Stock Down 1.8 %

Shares of OXB stock opened at GBX 273.50 ($3.55) on Friday. The firm’s fifty day moving average price is GBX 319.38 and its two-hundred day moving average price is GBX 379.08. Oxford Biomedica has a 1 year low of GBX 187.83 ($2.44) and a 1 year high of GBX 455 ($5.91). The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The firm has a market capitalization of £290.73 million, a P/E ratio of -2.03 and a beta of 1.09.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.